%0 Journal Article
%T Clinical Characteristics of Intravenous PEG
%A April Sykes
%A Belinda N. Mandrell
%A Christina Moore
%A Emily K. Browne
%A Sima Jeha
%A Zhaohua Lu
%J Journal of Pediatric Oncology Nursing
%@ 1532-8457
%D 2018
%R 10.1177/1043454217741868
%X Background: Asparaginase poses a substantial risk for hypersensitivity reactions during and after administration; however, these reactions vary by asparaginase formulation and administration route. It is imperative that nurses be knowledgeable of clinical symptoms associated with intravenous (IV) monomethoxypolyethylene glycol (PEG)-asparaginase reactions, as well as potential reaction timing. Purpose: This single institution retrospective study describes the clinical factors among patients with IV PEG-asparaginase hypersensitivity reactions. Methods: Reaction frequency and severity, dose, phase of treatment, and time between infusion initiation and reaction were collected on patients identified as having an IV PEG-asparaginase hypersensitivity reaction while undergoing acute lymphoblastic leukemia treatment. Results: Sixty-three patients (12.8%) developed a hypersensitivity reaction to IV PEG-asparaginase, with the reaction occurring during a median of 3 doses in both risk arms. Reactions were noted ¡Ü60 minutes after infusion initiation in 98% of patients, and no reactions were fatal. Conclusion: Nurses should carefully observe patients throughout the infusion and anticipate adverse reactions, particularly during the first 3 doses and first 10 minutes of each infusion. Patient and family education should include the rare risk of delayed reactions
%K PEG-asparaginase
%K hypersensitivity
%K reaction
%K allergy
%K nursing
%U https://journals.sagepub.com/doi/full/10.1177/1043454217741868